Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Friday, down -6.26% from the previous trading day, before settling in for the closing price of $21.25. Over the past 52 weeks, ARQT has traded in a range of $8.03-$21.29.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -0.98%. While this was happening, its average annual earnings per share was recorded 60.34%. With a float of $104.74 million, this company’s outstanding shares have now reached $119.80 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.67%, while institutional ownership is 98.85%. The most recent insider transaction that took place on Oct 01 ’25, was worth 469,074. In this transaction an insider of this company sold 24,261 shares at a rate of $19.33, taking the stock ownership to the 867,179 shares. Before that another transaction happened on Oct 02 ’25, when Company’s insider sold 20,739 for $20.04, making the entire transaction worth $415,574. This insider now owns 846,440 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.33 earnings per share (EPS), higher than consensus estimate (set at -0.43) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.34% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 3.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.74, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Compared to the last year’s volume of 2.08 million, its volume of 3.12 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 86.78%.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 83.92%, which indicates a significant increase from 70.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.94 in the past 14 days, which was higher than the 0.74 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.43, while its 200-day Moving Average is $14.71. Nevertheless, the first resistance level for the watch stands at $20.86 in the near term. At $21.81, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.31. If the price goes on to break the first support level at $19.41, it is likely to go to the next support level at $18.91. Should the price break the second support level, the third support level stands at $17.96.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 2.39 billion has total of 119,905K Shares Outstanding. Its annual sales at the moment are 196,540 K in contrast with the sum of -140,040 K annual income. Company’s last quarter sales were recorded 81,500 K and last quarter income was -15,890 K.
